A recently published phase III trial in Lancet Oncology, lower doses of adjuvant radiotherapy plus docetaxel "were associated with reduced toxicity and need for percutaneous endoscopic gastrostomy", impacting a patient's quality of life. Following 194 patients with stage III-IV HPV-associated oropharyngeal squamous cell carcinoma indicated grade 3 or higher toxic effect "of at least possible attribution to treatment...3 months after radiotherapy.." at 3% in the de-escalated adjuvant radiotherapy group compared to 11% in the standard of care group.
To read more about this study, click here.
De-escalating radiotherapy after surgery in HPV-associated oropharyngeal cancer is an important quality-of-life question, since these patients are often younger and live long enough to feel late toxicity for decades. If lower doses maintain control, sparing swallowing function and salivary glands is a genuine win. It is a debate the onc brothers podcast returns to often, because less treatment is only better when the evidence protects cure first.
ReplyDeleteThree percent versus eleven percent grade 3 or higher toxicity is a dramatic gap — and for HPV-positive oropharyngeal patients who are often cured young, swallowing function and salivary glands matter for decades, not months. The gastrostomy avoidance angle is especially meaningful; nothing says "quality of life" like keeping the ability to eat normally. De-escalation debates always come down to the same principle: cure first, and this phase III data suggests these patients can now have both.
ReplyDelete